Kevin P. Daly

Publications

1. Socioeconomic Status and Major Adverse Transplant Events in Pediatric Heart Transplant Recipients. JAMA Netw Open. 2024 Oct 01; 7(10):e2437255. View Abstract
2. Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial. Circulation. 2024 Nov 26; 150(22):1756-1766. View Abstract
3. International Society for Heart and Lung Transplantation Guidelines for the Evaluation and Care of Cardiac Transplant Candidates-2024. J Heart Lung Transplant. 2024 Oct; 43(10):1529-1628.e54. View Abstract
4. Improving Mechanical Circulatory Support Outcomes in Failing Bidirectional Glenn Physiology. Pediatr Cardiol. 2024 Jul 19. View Abstract
5. Pathology of explanted pediatric hearts: An 11-year study. Population characteristics and implications for outcomes. Pediatr Transplant. 2024 Jun; 28(4):e14742. View Abstract
6. Impact of a positive crossmatch on pediatric heart transplant outcomes. J Heart Lung Transplant. 2024 Jun; 43(6):963-972. View Abstract
7. Detecting and managing cardiac allograft vasculopathy within the transition from pediatric to adult heart transplantation care: Lighting the pathway ahead. J Heart Lung Transplant. 2024 02; 43(2):238-240. View Abstract
8. Medium-term Outcomes in Pediatric Heart Transplant Recipients Managed Using a Steroid Avoidance Immune Suppression Protocol. Transplantation. 2024 Jan 01; 108(1):e8-e14. View Abstract
9. Survivors of Pediatric Hematopoietic Stem Cell Transplantation Exhibit Progressive Diastolic Dysfunction Over Years of Follow-Up. Transplant Cell Ther. 2023 Dec; 29(12):774.e1-774.e8. View Abstract
10. ABO-Incompatible Heart Transplantation: Where Science, Society, and Policy Collide. J Card Fail. 2024 Mar; 30(3):486-487. View Abstract
11. External assessment and refinement of a population pharmacokinetic model to guide tacrolimus dosing in pediatric heart transplant. Pharmacotherapy. 2023 07; 43(7):650-658. View Abstract
12. Fecal Microbiota Transplant in Pediatric Solid Organ Transplant Recipients. Transplantation. 2023 09 01; 107(9):2073-2077. View Abstract
13. The teammate trial: Study design and rationale tacrolimus and everolimus against tacrolimus and MMF in pediatric heart transplantation using the major adverse transplant event (MATE) score. Am Heart J. 2023 06; 260:100-112. View Abstract
14. Apixaban Anticoagulation in Children and Young Adults Supported With the HeartMate 3 Ventricular Assist Device. ASAIO J. 2023 06 01; 69(6):e267-e269. View Abstract
15. Equity factors in pediatric transplant listing: Initial findings from a single center review. Pediatr Transplant. 2023 03; 27(2):e14467. View Abstract
16. The International Society for Heart and Lung Transplantation (ISHLT) guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2023 05; 42(5):e1-e141. View Abstract
17. Prognostic Value of Exercise Stress Echocardiography in Pediatric Cardiac Transplant Recipients. J Am Soc Echocardiogr. 2022 11; 35(11):1133-1138.e2. View Abstract
18. The Burden of Pediatric Heart Failure That Lies Just Under the Surface. J Am Coll Cardiol. 2022 05 17; 79(19):1929-1931. View Abstract
19. Experience with live attenuated varicella vaccination in pediatric heart transplant recipients: Considering a new path forward. J Heart Lung Transplant. 2022 08; 41(8):1027-1028. View Abstract
20. Waitlist Outcomes for Children With Congenital Heart Disease: Lessons Learned From Over 5000 Heart Transplant Listings in the United States. J Card Fail. 2022 06; 28(6):982-990. View Abstract
21. Pediatric heart transplant waiting times in the United States since the 2016 allocation policy change. Am J Transplant. 2022 03; 22(3):833-842. View Abstract
22. Giant Cell Myocarditis and Left Ventricular Apical Aneurysm in a Child With Severe Combined Immunodeficiency. Circ Cardiovasc Imaging. 2021 12; 14(12):1157-1158. View Abstract
23. Giant Cell Myocarditis in Children: Elusive Giant Cells Might Not Be the Only Clue. Pediatr Dev Pathol. 2022 Mar-Apr; 25(2):197-202. View Abstract
24. Clinical and hemodynamic characteristics of the pediatric failing Fontan. J Heart Lung Transplant. 2021 12; 40(12):1529-1539. View Abstract
25. ISHLT consensus statement for the selection and management of pediatric and congenital heart disease patients on ventricular assist devices Endorsed by the American Heart Association. J Heart Lung Transplant. 2021 08; 40(8):709-732. View Abstract
26. Assessment and Treatment of a Young Adult with Congenital Heart Disease and ADHD. J Dev Behav Pediatr. 2021 05 01; 42(4):340-342. View Abstract
27. Hepatorenal dysfunction assessment with the Model for End-Stage Liver Disease Excluding INR score predicts worse survival after heart transplant in pediatric Fontan patients. J Thorac Cardiovasc Surg. 2022 04; 163(4):1462-1473.e12. View Abstract
28. Retrospective Analysis of Clinical Genetic Testing in Pediatric Primary Dilated Cardiomyopathy: Testing Outcomes and the Effects of Variant Reclassification. J Am Heart Assoc. 2020 06 02; 9(11):e016195. View Abstract
29. The ABO-incompatible paradigm shifts only as far as allocation policy allows. J Heart Lung Transplant. 2020 07; 39(7):636-638. View Abstract
30. Brighter Future for Children with Congenital Heart Disease Requiring Heart Transplantation? A UNOS Registry Analysis over the Last Three Decades. J Heart Lung Transplant. 2020 Apr; 39(4S):S206-S207. View Abstract
31. The TEAMMATE Trial: Study Design and Rationale of the First Pediatric Heart Transplant Randomized Clinical Trial. J Heart Lung Transplant. 2020 Apr; 39(4S):S207-S208. View Abstract
32. Coagulation Monitoring Correlation with Bivalirudin Dosing in Pediatric Ventricular Assist Device Support. J Heart Lung Transplant. 2020 Apr; 39(4S):S467-S468. View Abstract
33. Marijuana in pediatric and adult congenital heart disease heart transplant listing: A survey of provider practices and attitudes. Pediatr Transplant. 2020 03; 24(2):e13640. View Abstract
34. Association of Clinical Rejection Versus Rejection on Protocol Biopsy With Cardiac Allograft Vasculopathy in Pediatric Heart Transplant Recipients. Transplantation. 2020 01; 104(1):e31-e37. View Abstract
35. Use of the terminal complement inhibitor eculizumab in paediatric heart transplant recipients. Cardiol Young. 2020 Jan; 30(1):107-113. View Abstract
36. Current evaluation and management of plastic bronchitis in the pediatric population. Int J Pediatr Otorhinolaryngol. 2020 Mar; 130:109799. View Abstract
37. T Cells Are Dominant Population in Human Abdominal Aortic Aneurysms and Their Infiltration in the Perivascular Tissue Correlates With Disease Severity. Front Immunol. 2019; 10:1979. View Abstract
38. Myocardial Infarct After Marijuana Inhalation in a 16-year-old Adolescent Boy. Pediatr Dev Pathol. 2019 Jan-Feb; 22(1):80-86. View Abstract
39. Heart failure after the Norwood procedure: An analysis of the Single Ventricle Reconstruction Trial. J Heart Lung Transplant. 2018 07; 37(7):879-885. View Abstract
40. Managing risk of surgical procedures in pediatric transplant recipients taking mTOR inhibitors: What is the optimal strategy? Pediatr Transplant. 2018 02; 22(1). View Abstract
41. Clinical practice patterns are relatively uniform between pediatric heart transplant centers: A survey-based assessment. Pediatr Transplant. 2017 Aug; 21(5). View Abstract
42. The Evolution of a Pediatric Ventricular Assist Device Program: The Boston Children's Hospital Experience. Pediatr Cardiol. 2017 Jun; 38(5):1032-1041. View Abstract
43. Development and validation of a major adverse transplant event (MATE) score to predict late graft loss in pediatric heart transplantation. J Heart Lung Transplant. 2018 04; 37(4):441-450. View Abstract
44. Into the hearts of babes: Stem cell therapy for pediatric heart failure. J Heart Lung Transplant. 2017 08; 36(8):830-832. View Abstract
45. Dilated Cardiomyopathy in a 2-Year-Old Infant. Clin Chem. 2017 01; 63(1):433-435. View Abstract
46. Vascular endothelial growth factor A is associated with the subsequent development of moderate or severe cardiac allograft vasculopathy in pediatric heart transplant recipients. J Heart Lung Transplant. 2017 Apr; 36(4):434-442. View Abstract
47. Cholesterol efflux capacity of high-density lipoprotein correlates with survival and allograft vasculopathy in cardiac transplant recipients. J Heart Lung Transplant. 2016 11; 35(11):1295-1302. View Abstract
48. Is Endomyocardial Biopsy a Safe and Useful Procedure in Children with Suspected Cardiomyopathy? Pediatr Cardiol. 2016 Oct; 37(7):1200-10. View Abstract
49. Finding the correct role for heart transplant in the treatment of hypoplastic left heart syndrome. J Heart Lung Transplant. 2016 Mar; 35(3):299-300. View Abstract
50. What Is the Role of Developmental Disability in Patient Selection for Pediatric Solid Organ Transplantation? Am J Transplant. 2016 Mar; 16(3):767-72. View Abstract
51. Use of [18F]FDG Positron Emission Tomography to Monitor the Development of Cardiac Allograft Rejection. Transplantation. 2015 Sep; 99(9):e132-9. View Abstract
52. Multicenter Analysis of Immune Biomarkers and Heart Transplant Outcomes: Results of the Clinical Trials in Organ Transplantation-05 Study. Am J Transplant. 2016 Jan; 16(1):121-36. View Abstract
53. Summary of the 2015 International Paediatric Heart Failure Summit of Johns Hopkins All Children's Heart Institute. Cardiol Young. 2015 Aug; 25 Suppl 2:8-30. View Abstract
54. Emerging science in paediatric heart transplantation: donor allocation, biomarkers, and the quest for evidence-based medicine. Cardiol Young. 2015 Aug; 25 Suppl 2:117-23. View Abstract
55. Translational implications of endothelial cell dysfunction in association with chronic allograft rejection. Pediatr Nephrol. 2016 Jan; 31(1):41-51. View Abstract
56. Circulating donor-derived cell-free DNA: a true biomarker for cardiac allograft rejection? Ann Transl Med. 2015 Mar; 3(4):47. View Abstract
57. Safety and efficacy of radiofrequency wire recanalization of chronic central venous occlusions. J Vasc Access. 2015 Jul-Aug; 16(4):309-14. View Abstract
58. Antibody depletion for the treatment of crossmatch-positive pediatric heart transplant recipients. Pediatr Transplant. 2013 Nov; 17(7):661-9. View Abstract
59. Effect of inhaled iloprost on the exercise function of Fontan patients: a demonstration of concept. Int J Cardiol. 2013 Oct 03; 168(3):2435-40. View Abstract
60. VEGF-C, VEGF-A and related angiogenesis factors as biomarkers of allograft vasculopathy in cardiac transplant recipients. J Heart Lung Transplant. 2013 Jan; 32(1):120-8. View Abstract
61. Key Features of the Intragraft Microenvironment that Determine Long-Term Survival Following Transplantation. Front Immunol. 2012; 3:54. View Abstract
62. Endomyocardial biopsy and selective coronary angiography are low-risk procedures in pediatric heart transplant recipients: results of a multicenter experience. J Heart Lung Transplant. 2012 Apr; 31(4):398-409. View Abstract
63. Sudden death after pediatric heart transplantation: analysis of data from the Pediatric Heart Transplant Study Group. J Heart Lung Transplant. 2011 Dec; 30(12):1395-402. View Abstract
64. Changes in echocardiographic measures of systolic and diastolic function in children 1 year after hematopoietic SCT. Bone Marrow Transplant. 2011 Dec; 46(12):1532-9. View Abstract
65. Variant translocation with a deletion of derivative (9q) in a case of Philadelphia chromosome positive (Ph +) essential thrombocythemia (ET), a variant of chronic myelogenous leukemia (CML) with a poor prognosis. Leuk Lymphoma. 2005 Dec; 46(12):1801-6. View Abstract
Show All Publications Show Fewer Publications